CT-179 for Recurrent or Newly Diagnosed Glioblastoma, Including With Radiation Therapy
Tests CT-179 in adults with recurrent or newly diagnosed glioblastoma.
Plain-language title generated from the registry record
Registry title: OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma
Key facts
- Where
- Brisbane, Heidelberg, Herston, Melbourne, and Sydney, AustraliaSee the 6 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07739017, who can take part
Where in Australia
- Princess Alexandra HospitalBrisbane, AustraliaNo longer taking part
- Austin HealthHeidelberg, AustraliaNo longer taking part
- Royal Brisbane and Women's HospitalHerston, AustraliaNo longer taking part
- The Alfred HospitalMelbourne, AustraliaNo longer taking part
- Royal North Shore HospitalSydney, AustraliaNo longer taking part
- St Vincent's HospitalSydney, AustraliaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Olivia Newton-John Cancer Research Institute
- Trial code
- NCT07739017
- Record updated
- 28 October 2026
- Original description
This is a first-in-human Phase 1 two-part, open-label, multi-center, dose escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and maximum tolerated dose (MTD) of CT-179 in patients with recurrent glioblastoma and newly diagnosed MGMT-unmethylated glioblastoma who are eligible to receive radiation therapy following surgery, and to establish the recommended Phase 2 dose.Read full original descriptionShow less
A Phase 1, Two-Part, Accelerated Dose Titration Trial of CT-179 as Monotherapy in the Treatment of Recurrent Glioblastoma and in Combination With Radiation Therapy in the Treatment of Newly Diagnosed MGMT-Unmethylated Glioblastoma
This is a first-in-human Phase 1 two-part, open-label, multi-center, dose escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and maximum tolerated dose (MTD) of CT-179 in patients with recurrent glioblastoma and newly diagnosed MGMT-unmethylated glioblastoma who are eligible to receive radiation therapy following surgery, and to establish the recommended Phase 2 dose.
Inclusion: Male or female aged ≥ 18 years at the time of signing informed consent; Supratentorial, histologically confirmed diagnosis of primary GBM that meets the current diagnostic classification: 2021 WHO Classification of Tumors of the Central Nervous System; KPS score ≥ 70; Adequate organ function; Contraception during study participation, as applicable; Able to swallow tablets.
Exclusion: Treatment with an investigational agent within the last 30 days excluding 5- aminolevulinic acid (5-ALA); Placement of Gliadel wafers or similar local therapy at time of surgery; Receive bevacizumab; Significant concomitant disorder or serious intercurrent illness; Dose of dexamethasone higher than 4 mg/day within 1 week of the first dose of study medication; Evidence of intracranial or intra-tumoral hemorrhage; History of prior malignancy, except adequately treated non-melanoma skin cancer, carcinoma in-situ of the cervix, or disease-free for more than 5 years; Treatment for HIV, hepatitis B, or hepatitis C; Any gastrointestinal disorder that could result in reduced absorption of CT-179; Any psychiatric illness or social situation that would limit compliance with study requirements.